The effects of antiangiogenic compound SU5416 in a rat model of pulmonary arterial hypertension
- PMID: 21116108
- DOI: 10.1159/000322011
The effects of antiangiogenic compound SU5416 in a rat model of pulmonary arterial hypertension
Abstract
Several lines of evidence indicate that vascular endothelial growth factor (VEGF) plays a prosurvival and antiapoptotic role in endothelial cells. SU5416 is the first VEGF receptor 2 inhibitor to enter clinical development for cancer therapy. A phase I/II study of SU5416 has been completed, and the results show that SU5416 is well tolerated in patients with terminal cancers. It has been shown that VEGF receptor blockade using SU5416 combined with chronic hypoxia results in severe angioproliferative pulmonary hypertension (PAH) with neointimal changes in adult rats. Although classic animal models of pulmonary hypertension (that is, the monocrotaline and hypoxic models) do not form obstructive intimal lesions in the peripheral pulmonary arteries, the SU5416 model has shown pulmonary arterial changes resembling plexiform lesions. Therefore, the SU5416 model of PAH has been used for some time, and it has thus contributed to a better understanding of the pulmonary hypertensive process. However, the mechanism by which SU5416 combined with chronic hypoxia can result in PAH with plexiform-like lesions in adult rats is complex and still remains to be fully elucidated. The most likely explanation is that there is increased apoptosis of endothelial cells in response to the loss of the survival signaling, creating conditions favoring the emergence of apoptosis-resistant cells with increased growth potential, that is, the endothelial cell hyperproliferation that might characterize the plexiform lesions of human PAH. The aim of the present review is to provide information useful for understanding a potent inhibitor of VEGF receptor tyrosine kinase, SU5416, and to better understand its use for generating animal models of PAH.
Copyright © 2010 S. Karger AG, Basel.
Similar articles
-
Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.Clin Cancer Res. 2008 Apr 1;14(7):2210-9. doi: 10.1158/1078-0432.CCR-07-1893. Clin Cancer Res. 2008. PMID: 18381963
-
Vascular endothelial growth factor-mediated angiogenesis inhibition and postoperative wound healing in rats.J Surg Res. 2002 Jun 1;105(1):43-7. doi: 10.1006/jsre.2002.6444. J Surg Res. 2002. PMID: 12069500
-
Triple combination of irradiation, chemotherapy (pemetrexed), and VEGFR inhibition (SU5416) in human endothelial and tumor cells.Int J Radiat Oncol Biol Phys. 2004 Nov 15;60(4):1220-32. doi: 10.1016/j.ijrobp.2004.07.689. Int J Radiat Oncol Biol Phys. 2004. PMID: 15519795
-
The role of vascular endothelial growth factor in pulmonary arterial hypertension. The angiogenesis paradox.Am J Respir Cell Mol Biol. 2014 Oct;51(4):474-84. doi: 10.1165/rcmb.2014-0045TR. Am J Respir Cell Mol Biol. 2014. PMID: 24932885 Review.
-
Role of angiogenesis inhibitors in acute myeloid leukemia.Cancer J. 2001 Nov-Dec;7 Suppl 3:S129-33. Cancer J. 2001. PMID: 11779083 Review.
Cited by
-
New models of pulmonary hypertension based on VEGF receptor blockade-induced endothelial cell apoptosis.Pulm Circ. 2012 Oct;2(4):434-42. doi: 10.4103/2045-8932.105031. Pulm Circ. 2012. PMID: 23372927 Free PMC article.
-
Revisiting the role of hypoxia-inducible factors in pulmonary hypertension.Curr Opin Physiol. 2019 Feb;7:33-40. doi: 10.1016/j.cophys.2018.12.003. Epub 2019 Jan 7. Curr Opin Physiol. 2019. PMID: 33103021 Free PMC article.
-
[Effect and mechanism of vascular endothelial growth factor-A on pulmonary vascular remodeling in neonatal rats with hypoxic pulmonary hypertension].Zhongguo Dang Dai Er Ke Za Zhi. 2021 Jan;23(1):103-110. doi: 10.7499/j.issn.1008-8830.2009005. Zhongguo Dang Dai Er Ke Za Zhi. 2021. PMID: 33476546 Free PMC article. Chinese.
-
Apelin and pulmonary hypertension.Pulm Circ. 2011 Jul-Sep;1(3):334-46. doi: 10.4103/2045-8932.87299. Pulm Circ. 2011. PMID: 22140623 Free PMC article.
-
Lack of bcr and abr promotes hypoxia-induced pulmonary hypertension in mice.PLoS One. 2012;7(11):e49756. doi: 10.1371/journal.pone.0049756. Epub 2012 Nov 12. PLoS One. 2012. PMID: 23152932 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
